Bleomycin Sulfate

Catalog No.S1214 Synonyms: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Size Price Stock Quantity  
USD 170 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 16 Publications

1 Customer Review

  • AACR 2011 Bleomycin Sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
In vitro

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnJelFWOOLCk{GwNFAh|ryv NVXZTYJmOjRiaNMg M4\vVYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MmW3NlYxQDh5MUG=
POLK WT NYfSenhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFzLkhihKnDueLCiUGuO:Kh|ryP NFzweJozPjB|MUSwNC=>
POLK KO MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTRwMERihKnDueLCiUGuPVLDqM7:TR?= MoCyNlYxOzF2MEC=
POLK CD NVP0ZoM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojoTWM2OD13LkW55qCKyrIkgJmxMlAxyqEQvF2= NF3WO4EzPjB|MUSwNC=>
RLE/Abca3 MnnRSpVv[3Srb36gRZN{[Xl? NEfo[W8xNjUEoN88US=> MkDQNVQ1yqCq NVziV4xscW6mdXPld{BiKG2xcoDoc4xw\2mlYXygZ4hidmenIH\yc40h\XCrdHjlcIlidC2uaXvlJI1wenCqb3zv[5khfG9iYTD3bYRmNCC|cILlZYQud3W2IH3vdpBpd2yxZ4pCpC=> MojXNlU4PjB3M{i=
PMCs MoPsSpVv[3Srb36gRZN{[Xl? MVSwMlHjiJN{wrFOwIcwdWx? NYHqbWdWOjUEoHi= NEP5RWJk[XW|ZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGVicILveIVqdiCuZY\lcEBw\iClb3zsZYdmdi2LwrC= M1zkOVI2PTl3NkSy
PMCs MkHTSpVv[3Srb36gRZN{[Xl? NWPONFJROC5{wrFOwIcwdWx? NEHFTowzPOLCk{eyxsBp NIjQR5BqdmS3Y3XzJIlv[3KnYYPld{BqdiC4aX3lcpRqdiCjbnSg{tEuW02DIIDyc5RmcW5? M{jLVVI2PTl3NkSy
PMCs M1;OXGZ2dmO2aX;uJGF{e2G7 MWGwMlLDqM7:Zz;tcC=> M3\vVVczKGh? MlrTbY5lfWOnczDk[YNz\WG|ZYOgbY4h[3m2b3vldoF1cW5vODDhcoQhTS2lYXTo[ZJqdiCycn;0[Ylv MWKyOVU6PTZ2Mh?=
PMCs MXzGeY5kfGmxbjDBd5NigQ>? MmP5NE4zyqEQvHevcYw> M{C5dVEzNzJ2L{S4JIg> NVHqWldZcW6lcnXhd4V{KGOnbHygcYloemG2aX;u MWeyOVU6PTZ2Mh?=
IMR-32 NYj6e4N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L3[lcvPeLKkkGyNEDDvWdxbXy= M4jiVlEz6ojUNEigbC=> MXvJR|UxRTZyINM1[{9udCCjdDD0bIUh\W6mIH;mJFI1KGi{czDv[kBqdmO3YnH0bY9v MUSyOVU{PjN2NR?=
HT1080 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS0PZNROSEQvF2= M4juOVI1KGkEoB?= MljocIVi\HNidH:gZUBIOi:PIHTlcIF6 MmnBNlU2OTh7NkG=
HT1080 NFS2VIdHfW6ldHnvckBCe3OjeR?= MXGxJO69VQ>? NIHXRXMzPCCqwrC= M17GV4lv\HWlZYOgZUBxd3SnboSg[4xw[mGuIFTORUBl[W2jZ3WgdoV{eG:wc3W= NVrTVHhCOjV3MUi5OlE>
HDFn MorJR5l1d3SxeHnjbZR6KEG|c3H5 NF7RUXY4OiCq M{DBdmlEPTB;OT6zNUXDqA>? MmS5NlUzPzZ5OUK=
THP-1 MlSxR5l1d3SxeHnjbZR6KEG|c3H5 MUm3NkBp NGqzXVNKSzVyPUSuO|cm MVOyOVI4Pjd7Mh?=
HT-29 M1TBfWN6fG:2b4jpZ4l1gSCDc4PhfS=> NIjndlI4OiCq MWjJR|UxRTFzLkS5KS=> NFfyU3YzPTJ5Nke5Ni=>
HCT116  MWLDfZRwfG:6aXPpeJkhSXO|YYm= M1;NXVczKGh? MlzFTWM2OD1zMT6zOEU> MXKyOVI4Pjd7Mh?=
A431 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vhSVUxNTJyMDDJWS=> MkfnOFjjiImq Mo[0bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NYDsbpN1OjVzMEGyPVk>
T24 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;Ec5E2OC1{MECgTXU> NIK1PJI1QOLCiXi= M3Ps[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MUmyOVExOTJ7OR?=
AY-27  MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXW1NE0zODBiSWW= MY[0PQKBkWh? MXXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MV6yOVExOTJ7OR?=
A549 M3vlZWZ2dmO2aX;uJGF{e2G7 MkXKNUDDvWdxbV|CpC=> NHvH[IcxNTR6IHi= MW\pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=> MUCyOFk3OzZ|NR?=
MLE12 NIXFfIdHfW6ldHnvckBCe3OjeR?= MV6xJOK2\y:vTNMg NGfwTmYxNTR6IHi= MV3pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=> NFSyeY0zPDl4M{[zOS=>
Jurkat M2nTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfwNlDjiIoQvH2= Mmn4NlTjiImqwrC= NGPDcVdienKnc4TzJJRp\SClZXzsJIN6[2ynIHH0JJRp\SCJMjDwbIF{\Q>? NEL3S3EzPDlzNki5Ny=>
HeLa  M{jmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nXRmlEPTB;MUCuNuKh|ryP NX\VSItkOjR5M{KzPVc>
C18-4 NVrQNHZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO2b2NVOC1zMECg{txO NGPncINqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NIjLTVQzPDV5MUm4Ni=>
BMG-1  M3rN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nwWFQxNzhywrFOwIcwdQ>? NIfhNI0{yqCq MWjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M3jyZVI{QTB4N{K2
A459 MY\BdI9xfG:|aYOgRZN{[Xl? M1zYclExKG2X MUC0PEBp NWrJOmFkcW6mdXPld{BieG:ydH;zbZM> NETXVYkzOzlyMke2Oi=>
MOCK NFrKblBCeG:ydH;zbZMhSXO|YYm= NInRWncyOCCvVR?= NVLSXVRnPDhiaB?= NF7STohqdmS3Y3XzJIFxd3C2b4Ppdy=> M2\jRlI{QTB{N{[2
MMP1 MV;BdI9xfG:|aYOgRZN{[Xl? MnXFNVAhdVV? NV:0fZZoPDhiaB?= MYjpcoR2[2W|IHHwc5B1d3Orcx?= MYCyN|kxOjd4Nh?=
A549 MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX31S2xROjByIN88US=> NXvjdJVxOjRiaNMg MmG2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MVGyN|gxPTd7Mx?=
HCT-116 NH3QR3BCeG:ydH;zbZMhSXO|YYm= MYKzM|cvPS9zNTFOwIcwdWx? NWPqUWtYPDhiaB?= M372[pJm\HWlZYOgeIhmKGyndnXsJI9nKEKOSDDheEBpcWeqIHPvcoNmdnS{YYTpc44> NIPDSY0zOzdyOE[2PC=>
HeLa NE\NboRCeG:ydH;zbZMhSXO|YYm= MYCzM|cvPS9zNTFOwIcwdWx? NYr6NVFHPDhiaB?= MmCxdoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> M{ntVVI{PzB6Nk[4
HCT116 NV3wRZlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;I[FAuOTByIN88[{9udA>? M1P4V|Q5KGh? NV7pbWtCcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NVrzWHduOjN3MUiyNFE>
NCM460 NV;kb2tQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXWxOphDOC1zMECg{txoN22u NEL1W401QCCq MX;pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MV6yN|UyQDJyMR?=
NT2  MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnKNlQhcMLi NYf1Tot3VER3ME20NFDjiIoEtXevcYw> M1vufVI{Ozh4NEKw
NT2  MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\ubVQ5KGh? NYnn[mZOVER3ME2xNFAhyrWpL33s NYjKboJOOjN|OE[0NlA>
NT2  NFfYdHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnTN5A4OiCq MVHMSFUxRTJy4pEJxtVoN22u MlmxNlM{QDZ2MkC=
NT2  M3zOXWFxd3C2b4Ppd{BCe3OjeR?= MYi0NFDjiIoEtXevcYw> M1XMUlI1KGkEoB?= NVHk[YRzcW6mdXPld{B{cWewaX\pZ4FvfCCrbnPy[YF{\XNiaX6gZ4F{eGG|ZT2zMFgtQSCjY4Tpeol1gcLi M4HZd|I{Ozh4NEKw
NTera-2 NXrXfndwTnWwY4Tpc44hSXO|YYm= M1PINVEzOCEQvHevcYw> NUTIe4NzPzJiaB?= NELUco1{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczC4MYl{d3C{b4P0ZY5mKGyndnXsdy=> MUKyNlgzPTN3NR?=
NCCIT M3v2U2Z2dmO2aX;uJGF{e2G7 MmH2NVIxKM7:Zz;tcC=> NFHzR|I4OiCq MnjLd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiOD3pd49xem:|dHHu[UBt\X[nbIO= M3;DOVIzQDJ3M{W1
NTera-2 NHP3U|FHfW6ldHnvckBCe3OjeR?= MYWxNlAh|rypL33s MlTXO|IhcA>? Mmmyd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiVFLBVnMhdGW4ZXzz MWmyNlgzPTN3NR?=
NCCIT MmDUSpVv[3Srb36gRZN{[Xl? M3r0V|EzOCEQvHevcYw> MnK5O|IhcA>? MlGxd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiVFLBVnMhdGW4ZXzz NF\mcZEzOjh{NUO1OS=>
NCCIT NGnCRXRHfW6ldHnvckBCe3OjeR?= NGXJNXAyOjBizsznM41t MV[3NkBp MYHzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCJU1igcIV3\Wy| NWfTUIQ4OjJ6MkWzOVU>
NTera-2 MVTGeY5kfGmxbjDBd5NigQ>? Mor3NVIxKM7:Zz;tcC=> MYm3NkBp MnjFd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiUILveIVqdiClYYLic456dCCuZY\lcJM> MmXENlI5OjV|NUW=
NCCIT NXv1fFhJTnWwY4Tpc44hSXO|YYm= Mn;hNVIxKM7:Zz;tcC=> NUDPSXlPPzJiaB?= Mnnod4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiUILveIVqdiClYYLic456dCCuZY\lcJM> NUewU3F{OjJ6MkWzOVU>
NTera-2 NGTYVYdHfW6ldHnvckBCe3OjeR?= MUKxNlAh|rypL33s NXvkW|FyPzJiaB?= Ml3Rd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiTGDPJIxmfmWucx?= MVeyNlgzPTN3NR?=
NCCIT MkL4SpVv[3Srb36gRZN{[Xl? NF;1d4IyOjBizsznM41t MoL5O|IhcA>? M3npfZNq\26rZnnjZY51dHliaX7jdoVie2W|IFzQU{Bt\X[nbIO= NXKwWGtuOjJ6MkWzOVU>
MDA-MB-468 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj0bIUx6oDVMkCwxsDPxGdxbVy= M1LpOVI1KGh? NV;rVmJ1cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M3voWVIzQDF7MUm2
231-H2N NVHGXnRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu1R|Ux6oDVMkCwxsDPxGdxbVy= MXSyOEBp NHfH[mNqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MXWyNlgyQTF7Nh?=
A549  NUf3cVV6TnWwY4Tpc44hSXO|YYm= NFHqSVkzODBxNECwJO69VQ>? NVr5NFd3emW|dXz0d{BqdiCjIHTvd4UuemW|cH;ud4l3\SCrbnPy[YF{\SCrbjDSU3M> NH;N[WEzOjd5M{[5Oy=>
A549  MUnGeY5kfGmxbjDBd5NigQ>? NFftV28xNTRyMDFOwG0> M{j3XFIuPDhiaB?= MU\jZZV{\XNibX;y[UBufESQQTD0bIFvKG6GTlGg[IFu[Wen M3ns[VIzPzd|Nkm3
A549  NFezfHlHfW6ldHnvckBCe3OjeR?= NF7Ob3QyODBizszNxsA> NETjSJQx6oDVNEigbC=> M1PKUoNifXOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> MXyyNlc4OzZ7Nx?=
A549  M1rOemZ2dmO2aX;uJGF{e2G7 M3P0RVExOCEQvF5CpC=> Mm\lNQKBmzR6IHi= NYLkRW1J[2G3c3XzJHBMTDFiY3zlZZZi\2V? M3P5VlIzPzd|Nkm3
A549  NGXtSYdHfW6ldHnvckBCe3OjeR?= NF3BPYgyODBizszNxsA> NIPPfW8x6oDVNEigbC=> MnvzZ4F2e2W|IH3peI9kcG:wZILpZYwhdG:lYXzpfoF1cW:wIH;mJGJigA>? NGj5eZgzOjd5M{[5Oy=>
A549  MX;GeY5kfGmxbjDBd5NigQ>? NXrvd|RrOTByIN88UeKh MnvRNQKBmzR6IHi= MUjk[YNz\WG|ZYOgUW1RKGGwZDDBWHAhdGW4ZXzz M1KwNFIzPzd|Nkm3
MCF-7/Her-18  MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LXeVAvPDJvMUewNEDPxGdxbVy= MmP0NlQhcA>? MUfpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MXqyNlYzOTRyNB?=
MCF-7 NEezenBRTFRxUFPJJHRz\WG2bXXueC=> NGnsXIIxNjJ3IN88[{9udC5? Mn[zNU01KGh? NHPtW4Z{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 MX[yNlU6OTJ6NB?=
MDA-MB-231 NFXoTldRTFRxUFPJJHRz\WG2bXXueC=> NVrqc3lsOC5{NTFOwIcwdWxw MWixMVQhcA>? M3T6b5Npd3e|IIPp[45q\mmlYX70JEhRyqB:IECuNFUqKGO7dH;0c5hq[yCnZn\lZ5Q> NXWw[W97OjJ3OUGyPFQ>
MDA-MB-235  MV\QSHQwWEOLIGTy[YF1dWWwdB?= MV6wMlI2KM7:Zz;tcE4> NIr4OWgyNTRiaB?= M4qy[pNpd3e|IIPp[45q\mmlYX70JEhRyqB:IECuNFUqKGO7dH;0c5hq[yCnZn\lZ5Q> MY[yNlU6OTJ6NB?=
MCF-7 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPo[o5WOC1{IN88[{9udC5? M{XLfFI1NzR6IHi= NViycZhQTUN3ME2xMlIh|rypL33M Ml7RNlI2QTF{OES=
NCCIT  NH3KU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j4NlIx6oDVMUSwxsDPxGdxbXy= Mn:wO|IhcA>? NHzhcpRNTDVyPUGyNOKh|rypL33sxsA> NGfpPZEzOjV4MkG2NC=>
NCCIT  M1XXc2Z2dmO2aX;uJGF{e2G7 M3jYcVczKGh? M{POeJNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvMzDhZ5Rqfmm2edMg M{DZXlIzPTZ{MU[w
NCCIT  NHj4R4dHfW6ldHnvckBCe3OjeR?= MW[3NkBp MXLzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNThiYXP0bZZqfHoEoB?= MXeyNlU3OjF4MB?=
NCCIT  MoDkSpVv[3Srb36gRZN{[Xl? M2XZUlczKGh? NIq4b|N{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUmgZYN1cX[rdIpCpC=> NI\mN3EzOjV4MkG2NC=>
NCCIT  NUT3SZpRTnWwY4Tpc44hSXO|YYm= NEPp[VM4OiCq Mmjmd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiQlHYJIxmfmWu M13kSFIzPTZ{MU[w
NCCIT  M1HEbmZ2dmO2aX;uJGF{e2G7 NV3JSZptPzJiaB?= MWrzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgRoNtNTJiY3;ueIVvfA>? M2flU|IzPTZ{MU[w
NCCIT  MnPxSpVv[3Srb36gRZN{[Xl? MYG3NkBp MorFd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGN6fC2lIHzleoVt M1u0elIzPTZ{MU[w
HeLa M{O3T2Z2dmO2aX;uJGF{e2G7 M1LwPVMxNzdyIN88[{9udA>? NW\xRXNkOjUEoHi= M2m0Uolv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqHB3M,-8kGFVVSyyMkJCpIFv\MLiR1HESFQ2 MVGyNlQ5Pzl|Nx?=
MCF-7  NEfWN3FHfW6ldHnvckBCe3OjeR?= MoXPN|AwPzBizsznM41t NIXacYozPMLiaB?= NF\PfHBqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCyNURvwKxCXE1ucEKxxsBidmUEoFfBSGQ1PQ>? NX\Zd2N3OjJ2OEe5N|c>
HeLa MlTCR5l1d3SxeHnjbZR6KEG|c3H5 MmnoN|AwPzBizsznM41t NHjkdZgzPMLiaB?= NEjJXXdqdmS3Y3XzJIhq\2iueTDzbYdvcW[rY3HueEBt\X[nbIOgc4Yh\nKjZ33lcpRm\CCGTlGgdoVt\WG|ZTDpcpRwKHSqZTDjfZRweGyjc32= NVTmUGhDOjJ2OEe5N|c>
MCF-7  NFXnUlZEgXSxdH;4bYNqfHliQYPzZZk> NHPvT3U{OC95MDFOwIcwdWx? MUiyOOKhcA>? NHjCfI9qdmS3Y3XzJIhq\2iueTDzbYdvcW[rY3HueEBt\X[nbIOgc4Yh\nKjZ33lcpRm\CCGTlGgdoVt\WG|ZTDpcpRwKHSqZTDjfZRweGyjc32= NXm2ZlVvOjJ2OEe5N|c>
NT2 NYPhSWlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLMNVAxNTZyMNMg{txoN22u NFO4dGEzPCCq MW\JR|UxRTRyMDFCuYcwdWx? M3LQW|IzPDZ7OUWy
NT2 NF7iZ4xHfW6ldHnvckBCe3OjeR?= MUi0NFDDqM7:Zz;tcC=> NHzwfoIzPCCq M2ny[JNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvMzy4MFkh[WO2aY\peJnDqA>? NYfMPId6OjJ2Nkm5OVI>
NT2 NEf2fnhHfW6ldHnvckBCe3OjeR?= MXe0NFDDqM7:Zz;tcC=> MYqyOEBp NWPrbGo6e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgRmFZKGyndnXs NYfMS|JDOjJ2Nkm5OVI>
NT2 MmG2SpVv[3Srb36gRZN{[Xl? M2X6WlQxOMLizsznM41t M4Xa[|I1KGh? Mom1d4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiQnPsMVIhdGW4ZXy= M{[xb|IzPDZ7OUWy
CHO NHy4N4JHfW6ldHnvckBCe3OjeR?= Mk\NNk42yqEQvHevcYw> M3fwb|E5KGhxNjDk NYHSO5dRcW6mdXPld:KheGW{c3nzeIVv[2Vib3[gZ4hzd22xc3;t[UBl[W2jZ3W= NYDWXpVZOjJ{M{CxPVU>
Jurkat M3iwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vsTVAuOTBywrFOwIcwdWx? M{Dl[lI1KGh? NV32TY5N[XK{ZYP0d{B1cGViY3XscEBkgWOuZTDheEB1cGViR{KgdIhie2V? M{WwclIzOjJ|M{Oy
Jurkat NYW2Z3VnTnWwY4Tpc44hSXO|YYm= MYqzNOKh|rypL33s M4nVbVI1KGh? NXnRNoZ{cW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDjfYNtcW6|IFSzMEBCKGGwZDDCNS=> M2L1RlIzOjJ|M{Oy
Jurkat M4XlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGwMVExOMLizsznM41t M3;jZ|I1KGh? MYHpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKge4l1cCCjbjDJR|UxKH[jbIXlJI9nKDFyMN88[{9uVA>? M2jQflIzOjJ|M{Oy
Jurkat MmP4SpVv[3Srb36gRZN{[Xl? NFfm[ZI{OMLizsznM41t MknXNlQhcA>? NX\tS2N6cW6lcnXhd4V{KHSqZTDl[oZm[3Rib3[gdJlkdmmmaX;u[UBwdiCyaH;zdIhwenmuYYTpc44hdGW4ZXzzJI9nKGirc4TvcoUhUDKDLmi= NIi3V|UzOjJ{M{OzNi=>
U2OS EGFPnls MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnKfZIxNTMEoN88[{9udA>? NWLRTWpuOjRiaB?= MmjObY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NYTQWWdUOjF6MUGwNFc>
U2OS KuEnls NHXUb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXNZmZ4OC1{wrFOwIcwdWx? MWqyOEBp M3XG[IlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MmHLNlE5OTFyMEe=
MCF-7 M1XpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIKxbVMxNTRyMDFOwG0> NH;CbJE4OiCq NYnicYRCVEN3ME2xOVEvQMLizszN M33uUlIyPzB|Mkmx
MCF-7/Adr  MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HEd|AuPDByIN88US=> NILuRlY4OiCq Ml;tUGM2OD13OD61xsDPxE4EoB?= M{O2TVIyPzB|Mkmx
WI-38 Mki0SpVv[3Srb36gRZN{[Xl? MmnmNE81OC96MPMAje69\y:vbNMg MWezJIg> NVm1RW1vcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? MmTuNlE2QTl4MUK=
hBMSC NFj3PFlHfW6ldHnvckBCe3OjeR?= MmXRNE81OC96MPMAje69\y:vbNMg MWizJIg> MnThbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NEHNN4MzOTV7OU[xNi=>
NCI-H23 NX\mWItRTnWwY4Tpc44hSXO|YYm= MoewNE81OC96MPMAje69\y:vbNMg MX2zJIg> MmfybY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NXXKdnFlOjF3OUm2NVI>
A-549 M1\D[mZ2dmO2aX;uJGF{e2G7 MViwM|QxNzhy4pEJ{txoN22uwrC= MYKzJIg> NIPKNZdqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh MYSyNVU6QTZzMh?=
PBL  M1;KRmZ2dmO2aX;uJGF{e2G7 M{XrVVAwPDBxOEFihKnPxGdxbX|CpC=> NUnRWJY6OyCq NUS1U4txcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? NFzK[5kzOTV7OU[xNi=>
pol β −/− NVLp[IlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn22NE4zPS1{MEFCpO69\y:vbB?= NXf6[4l5OjUEoHi= NWGybWFZ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li MkfyNlEzPTF7NES=
pol β +/+ MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjSfZJzOC5{NT2yNFDDqM7:Zz;tcC=> NED4NFEzPMLiaB?= NGDr[phl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4l1cCCrbnPy[YF{cW6pIHPvcoNmdnS{YYTpc45{yqB? NH3nRpMzOTJ3MUm0OC=>
pol β −/− M4TJd2Z2dmO2aX;uJGF{e2G7 NX\I[WZqOC1{LkWg{txoN22u MkX1NkBp MX\jZZV{\XNiRF7BJIRidWGpZR?= NWTD[XFpOjF{NUG5OFQ>
pol β +/+ NGfidWNHfW6ldHnvckBCe3OjeR?= M1LqWVAuOi53IN88[{9udA>? NFvTfFYzKGh? M2nYbYNifXOnczDEUmEh\GGvYXfl NGnUZ3MzOTJ3MUm0OC=>
pol β −/− MlPBSpVv[3Srb36gRZN{[Xl? MXqwMVUh|rypL33s MWm0PEBp M1\zcYNifXOnczDtbYNzd263Y3zleZMh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> M2Lsd|IyOjVzOUS0
pol β +/+ NU\oOJRxTnWwY4Tpc44hSXO|YYm= NXG1VIM5OC13IN88[{9udA>? NFT1VZc1QCCq NEDuOpJk[XW|ZYOgcYlkem:wdXPs[ZV{KGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> MV[yNVI2OTl2NB?=
TK6  MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnyNlUuOTVyIN88[{9udA>? NHLoNlE6PiCq MXTpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M4PyeFIyODhzNEi3
TK6  sLUC+Apn1 MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVP3NoZ5OjVvMUWwJO69\y:vbB?= M{XpWFk3KGh? NFXkWI5qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MU[yNVA5OTR6Nx?=
TK6 sAPE1+Apn1 M4nhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrzRoszPS1zNUCg{txoN22u NEWyXoU6PiCq M1Xp[ZNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEBoem:5dHig[I9{\SCmZYDlcoRmdnSueR?= NE[1O2YzOTB6MUS4Oy=>
HCT116 NYjVT5F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrzNlUuOTVyIN88[{9udA>? NFvaO4k6PiCq NFTYT2VqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 Mnq5NlExQDF2OEe=
HCT116 sLUC+Apn1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHOW4dKOjVvMUWwJO69\y:vbB?= NFrRS2c6PiCq M3:1[olvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M{HCPVIyODhzNEi3
HCT116 sAPE1+Apn1 NVr0dXVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjN[lczPS1zNUCg{txoN22u M2rKSlk3KGh? M{PDeZNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEBoem:5dHig[I9{\SCmZYDlcoRmdnSueR?= NVriWYxUOjFyOEG0PFc>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LRP6 / Wnt5AB / Dvl2 / β-catenin; 

PubMed: 27649046     


CRL-1490 cells were treated with the indicated concentrations of bleomycin for either 12 or 24 h, and then probed for canonical Wnt proteins LRP6, Wnt5AB, Dvl2, and β-catenin. 

phospho-eIF2α / eIF2α; 

PubMed: 23762310     


Western blotting analysis of phosphorylated, total eIF2α and β-actin in CT26 treated 24 h with the indicated drugs. BLM: Bleomycin

cytochrome c; 

PubMed: 20154224     


mitochondrial release of cytochrome c was detected by Western blot in cytosolic extract and analyzed by band densitometry. Data show the means of four independent experiments ± SE. *Statistical significance from control, P < 0.05. Representative Western blots are shown.

Bcl-xl; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-xL.

Bcl-2; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-2.

27649046 23762310 20154224
Immunofluorescence
LC3; 

PubMed: 23762310     


CT26 cells were cultured on glass slides and treated with indicated drugs for 24 h. The cells were then submitted to anti-LC3 (green) and DAPI (blue) labeling and observed under an epifluorescence microscope. BLM: Bleomycin

23762310
ELISA
HMGB1; 

PubMed: 23762310     


HMGB1 was titrated with ELISA method in supernatant of CT26 cells treated 24 h with indicated drugs. BLM: Bleomycin

23762310
In vivo Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

Protocol

Cell Research:

[4]

+ Expand
  • Cell lines: ADIPO-P2 cells
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30 minutes
  • Method:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD-1 mice
  • Formulation: Saline
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: Administered via i.t.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1512.62
Formula

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
in solvent
Synonyms NSC125066

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • Answer:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate price | Bleomycin Sulfate cost | Bleomycin Sulfate solubility dmso | Bleomycin Sulfate purchase | Bleomycin Sulfate manufacturer | Bleomycin Sulfate research buy | Bleomycin Sulfate order | Bleomycin Sulfate mouse | Bleomycin Sulfate chemical structure | Bleomycin Sulfate mw | Bleomycin Sulfate molecular weight | Bleomycin Sulfate datasheet | Bleomycin Sulfate supplier | Bleomycin Sulfate in vitro | Bleomycin Sulfate cell line | Bleomycin Sulfate concentration | Bleomycin Sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID